Focal adhesions are randomly distributed across the ventral surface or along the edge of epithelial cells. In fibroblasts they orient centripetally and concentrate at a few peripheral sites connecting long F-actin stress fibers, causing a typical elongated, contractile morphology. Extensive remodeling of adhesions in fibroblasts also takes part in fibronectin fibrillogenesis, a process that depends on Rho-mediated contractility and results in the formation of a fibronectin matrix. Our current study shows that all these fibroblast characteristics are controlled by the ability of integrin α5β1 to bind soluble fibronectin molecules in their compact inactive conformation. The hypervariable region of the ligand-binding I-like domain of integrin α5β1 supports binding of soluble fibronectin. This supports the distribution of centripetally orientated focal adhesions in distinct peripheral sites, Rho activation and fibronectin fibrillogenesis through a mechanism that does not depend on Syndecan-4. Integrin αvβ3, even when locked in high affinity conformations for the RGD recognition motif shows no appreciable binding of soluble fibronectin and, consequently, fails to support the typical fibroblast focal adhesion distribution, Rho activity and fibronectin fibrillogenesis in the absence of integrin α5β1. The ability of α5β1 integrin to interact with soluble fibronectin may thus drive the cell-matrix adhesion and cytoskeletal organization required for a contractile, fibroblast-like morphology, perhaps explaining why α5β1 integrin, similarly to fibronectin, is essential for development.
Integrins consist of non-covalently linked α- and β-subunits. Ligands, including extracellular matrix (ECM) components such as fibronectin, are bound to the integrin extracellular globular head domain whereas a multitude of cytoskeletal adaptor proteins interact via the cytoplasmic tail. Thus, integrins create a link between the ECM and the actin cytoskeleton. Ligand binding can be modulated at the level of integrin clustering (avidity) or by activation of integrins through conformational changes in the extracellular ligand-binding domains (affinity) (Calderwood, 2004; Takagi and Springer, 2002). For instance, binding to soluble ligands through integrin α5β1, αvβ3 or αIIbβ3 can be enhanced more than 20-fold by divalent cations or stimulatory antibodies, leading to firm adhesion of cells that show no appreciable adhesion to immobilized ligands in the absence of such stimuli (Danen et al., 1995; Mould et al., 1995; Smith et al., 1994). In turn, integrin-mediated adhesion can modulate various intracellular signaling cascades (Hynes, 2002). Following cell adhesion to the ECM, integrins and associated proteins assemble in cell-matrix adhesions, which organize the actin cytoskeleton. In epithelial cells, focal adhesions are randomly distributed across the ventral surface or along the cell border. In mesenchymal cells such as fibroblasts, they orient centripetally and concentrate in a few peripheral sites connecting long F-actin stress fibers, causing a typical elongated, contractile morphology.
Fibronectin is essential for embryonic development and is abundantly present in the ECM associated with wound healing and angiogenesis (Hynes and Zhao, 2000). Mesenchymal cells secrete compact and inactive soluble fibronectin dimers, which are assembled into insoluble fibronectin fibrils following their interaction with cell surface receptors of the integrin and syndecan families (Wierzbicka-Patynowski and Schwarzbauer, 2003). Fibronectin fibrils are assembled into a matrix that is important for anchorage of cells and guides cell migration during embryonic development and wound healing (Hynes and Zhao, 2000). Integrins α5β1, α8β1, αvβ1, αvβ3, αIIbβ3, αvβ5, αvβ6 and αvβ8 recognize the common integrin-binding motif Arg-Gly-Asp (RGD) that is found in many ECM components, including fibronectin (Danen and Sonnenberg, 2003). Of these integrins, α5β1 is particularly efficient in mediating fibronectin matrix assembly, although others can compensate for its absence to some extent (Wennerberg et al., 1996; Wu et al., 1996; Yang and Hynes, 1996). Fibronectin fibrillogenesis requires extensive remodeling of cell-matrix adhesions (Pankov et al., 2000), and contractility of the actin-myosin cytoskeleton, which is stimulated by the small GTPase Rho through activation of myosin-II. Contractility drives fibronectin fibrillogenesis by creating sufficient tension to stretch the compact fibronectin dimers and expose intermolecular fibronectin-binding sites (Zhong et al., 1998).
Integrin-mediated cell adhesion triggers a rapid inactivation of the small GTPase RhoA (Ren et al., 1999), which is important to relieve contractility and allow cell spreading. As cell spreading ends, Rho-mediated cytoskeletal contractility gradually increases, which coincides with maturation of focal adhesions and initiation of fibronectin fibrillogenesis. We previously reported that β1 integrins are dispensable for cell spreading but required to support this second phase (Danen et al., 2002; Danen et al., 2005). In the studies reported here, we expressed different wild-type, chimeric and mutant integrin subunits in cells lacking the Itgb1, Itgb3 or Itga5 integrin genes, or silenced expression of integrin β1 or syndecan-4 (SDC4) to study how they organize cell-matrix adhesions, cytoskeletal contractility and fibronectin matrix assembly. Our findings suggest extensive reciprocal signaling between fibronectin and the actin cytoskeleton, which occurs selectively through integrin α5β1 and couples binding of soluble fibronectin dimers to a fibroblast-like distribution of focal adhesions, Rho-mediated contractility and fibronectin fibrillogenesis.
Integrin α5β1 promotes fibroblast-like organization of cell-matrix adhesions, Rho activity and fibrillogenesis
We have previously shown that β1 integrins promote a fibroblast-like distribution of cell-matrix adhesions and a contractile, elongated cell shape that is associated with high levels of RhoA activity, focal adhesion turnover and fibronectin matrix assembly whereas αvβ3 fails to do so in the absence of β1 integrins (Danen et al., 2002; Danen et al., 2005) (see Fig. 1A). There is also evidence that overexpression of αvβ3 can stimulate RhoA activity and cytoskeletal contractility in leukocytes and CHO cells (Butler et al., 2003; Miao et al., 2002). Here, we determined the importance of αvβ3 in these processes using mouse embryonic fibroblasts (MEFs) isolated from Itgb3-knockout mice. The levels of GTP-RhoA in β3-integrin-null MEFs were similar to those in MEFs isolated from wild-type littermates, indicating that RhoA activation does not require αvβ3 integrin (Fig. 1B, supplemental material Fig. S1A). Similarly, fibronectin matrix assembly mediated by β3-integrin-null MEFs occurred equally efficiently as that mediated by wild-type MEFs (Fig. 1C). Ectopic expression of β3 integrin did not further stimulate RhoA activity, whereas increased expression of β1 integrin led to enhanced activation of RhoA (Fig. 1B). Increased expression of β1 integrins in β3-integrin-null MEFs also led to a more elongated, contractile cytoskeletal organization, whereas the presence or absence of β3 integrin did not affect morphology (Fig. 1D). Moreover, suppression of endogenous β1 integrins using Itgb1-specific siRNAs caused a phenotypic switch in wild-type MEFs characterized by increased cell spreading, more random distribution of focal adhesions and formation of cell-cell adhesions (Fig. 1E,F). We were unable to completely silence β1 integrin expression in MEFs and the level of suppression reached did not lead to detectable reduction of RhoA-GTP levels (not shown). Nevertheless, the conversion to a more epithelial morphology (strongly resembling that of β1-integrin-deficient GEβ3 cells; Fig. 1A) upon β1 integrin silencing was in complete agreement with our previous findings using β1-integrin-null cells. Silencing expression of β1 integrins in Itgb3-knockout MEFs caused cell rounding but the cells that remained attached resembled GE11 β1-integrin-knockout cells, growing in islands with extensive cell-cell contacts (Fig. 1E,F; compare with Fig. 3A, left image).
Of the β1 integrins, α5β1 integrin most efficiently supports fibronectin matrix assembly but integrins α8β1, α4β1 and αvβ1 can also mediate cell adhesion to immobilized fibronectin. To determine whether α5β1 integrin is the β1 integrin responsible for the typical fibroblast-like characteristics described above, we used differentiated Itga5-knockout ES cells (EA5). RhoA-GTP levels were very low in EA5 cells and restoring expression of α5 integrin induced efficient RhoA-GTP loading (Fig. 2A, supplementary material Fig. S1B). Expression of an α5αv integrin chimera, consisting of the α5 integrin extracellular and transmembrane domains and the αv integrin cytoplasmic domain similarly induced RhoA-GTP loading, indicating that α5-integrin-specific sequences in the cytoplasmic tail are not required for enhancing RhoA activation (Fig. 2A). The very low RhoA-GTP levels in EA5 cells were accompanied by a flat circular cell shape with dispersed focal adhesions. Expression of α5 integrin or α5αv integrin induced a reorganization of the cytoskeleton with long F-actin stress fibers connecting peripheral focal adhesions (Fig. 2B). Likewise, fibronectin fibrillogenesis was strongly enhanced in the presence of α5 integrin or α5αv integrin in EA5 cells (Fig. 2C), which is consistent with previous findings (Sechler et al., 1997; Wu et al., 1993).
Together, these results demonstrate that the typical fibroblast-like elongated, contractile morphology that is associated with high levels of Rho-GTP and fibronectin matrix assembly do not require αvβ3 integrin and are primarily stimulated by α5β1 integrin.
The extracellular ligand-binding domain of α5β1 integrin specifies fibroblast morphology, RhoA activation and fibronectin fibrillogenesis
In addition to the obvious essential role of the extracellular domain in ligand binding, the integrin transmembrane and cytoplasmic domains regulate ligand affinity and avidity by controlling integrin conformation and clustering (Calderwood, 2004; Li et al., 2003; Luo et al., 2007). The β1 integrin cytoplasmic domain is exchangeable with that of β3 integrin with no effect on Rho activation, fibronectin fibrillogenesis or fibroblast morphology when expressed in β1-integrin-deficient GE11 cells (Danen et al., 2002). To test whether specific amino acid residues in the transmembrane domain of β1 integrin are required for α5β1-integrin-mediated support of fibroblast morphology, Rho activity, and fibronectin fibrillogenesis, we generated a chimeric β1e3t+i subunit, consisting of a β1 integrin extracellular domain and β3 integrin transmembrane and cytoplasmic domains. When expressed in β1-integrin-deficient GE11 cells (supplementary material Fig. S1C), this chimera promoted focal adhesion distribution and enhanced RhoA activity similar to wild-type β1 (Fig. 3A,B). Moreover, similarly to wild-type β1 integrin, β1e3t+i efficiently supported fibronectin matrix assembly (Fig. 3C), arguing against a specific role of the transmembrane and cytoplasmic domains of β1 integrin in these processes. By contrast, expression of a β1[D130A] integrin subunit, containing a mutation in the extracellular I-like domain that abrogates ligand binding (Takada et al., 1992), failed to induce RhoA activation, a mesenchymal morphology, or fibronectin fibrillogenesis (Fig. 3, supplementary material Fig. S1C).
These findings indicate that the support of a fibroblast-like, contractile morphology associated with Rho activity and fibronectin fibillogenesis by α5β1 integrin is strictly dependent on ligand binding to its extracellular domain. Other regions of this integrin can be exchanged with corresponding regions of αvβ3 integrin without consequence and surface expression of α5β1 integrin without ligand interaction, which could affect (expression of) other surface receptors, is insufficient to support these processes.
The ability to bind to soluble fibronectin dimers correlates with RhoA activity and fibronectin fibrillogenesis
Many different integrins (including α5β1 integrin and αvβ3 integrin) can recognize the RGD motif and mediate cell adhesion to immobilized (stretched) fibronectin. However, we observed that all integrin β-subunits that supported a fibroblast-like cytoskeletal organization, Rho activity and fibronectin fibrillogenesis (β1, β1e+t3i and β1e3t+i), efficiently bound to soluble (compact and inactive) fibronectin dimers whereas the other β-subunits tested (β3, β1[D130A]) did not (Fig. 3D). This suggested that differences in binding to soluble fibronectin between α5β1 integrin and αvβ3 integrin could explain not only the particular efficiency with which α5β1 integrin mediates fibronectin matrix assembly but also the different abilities of these integrins to support a fibroblast-like, contractile cytoskeletal organization and Rho activation.
We used mutants of β3 integrin, which, in the context of αIIbβ3, are locked in a low- or high-affinity conformation for the RGD sequence in fibrinogen (Luo et al., 2003; Luo et al., 2004), the integrin recognition sequence that is also present in the central cell-binding domain of fibronectin. Expression of a low-affinity β3[T329C; A347C] did not affect the poorly spread GE11 cell morphology (Fig. 4A center image; compare with Fig. 3A left image). Expression of the high-affinity β3[N305T] and β3[V332C; M335C] mutants stimulated cell spreading but distribution of focal adhesions in these cells was similar to those expressing wild-type β3 integrin (Fig. 4A; compare with Fig. 1A right image). In line with these morphological similarities, the high-affinity mutants failed to enhance RhoA-GTP levels or fibronectin fibrillogenesis in the absence of β1 integrin as also seen with wild-type αvβ3 integrin (Fig. 4B,C). As expected, based on findings in CHO cells (Luo et al., 2003; Luo et al., 2004) the β3[N305T] and β3[V332C; M335C] mutations strongly increased αvβ3-integrin-mediated binding of GE11 cells to soluble RGD (Fig. 5A). However, even in the presence of the activating divalent cation, manganese, locking αvβ3 integrin in a high affinity state for RGD failed to induce binding to soluble fibronectin (Fig. 5B,C). Again, α5β1 integrin efficiently bound soluble fibronectin in these experiments which could be competed with unlabeled fibronectin (Fig. 5B,C).
These results demonstrate that although RGD is a common recognition motif, affinity for RGD does not necessarily indicate binding to all RGD-containing ligands. The central cell-binding domain of compact soluble fibronectin dimers appears to be only available for binding to α5β1 and not to αvβ3 integrin. Notably, this indicates that efficient binding to soluble fibronectin dimers might in fact underlie the efficiency with which α5β1 integrin supports a fibroblast-like distribution of focal adhesions, contractile cell shape and Rho-mediated cytoskeletal contractility that drives fibronectin fibrillogenesis.
Specificity in the I-like domain controls binding of soluble fibronectin, focal adhesion distribution, Rho-mediated contractility and fibronectin matrix assembly independently of syndecan-4
Since ligand binding is required for α5β1 integrin to support a contractile, fibroblast-like morphology and Rho activity (β1[D130A]; Fig. 3) and since its ability to efficiently bind soluble fibronectin dimers appeared to underlie the difference between α5β1 integrin and αvβ3 integrin in this respect (Fig. 5), we analyzed a more subtle mutation in the I-like domain that participates in ligand binding. Exchanging the CTSEQNC hypervariable sequence in the I-like domain of β1 integrin with the corresponding region of β3 integrin has been shown to cause a shift in ligand specificity that leads to adhesion to vitronectin, von Willebrand factor and fibrinogen without affecting adhesion to immobilized (stretched) fibronectin (Takagi et al., 1997). We expressed such a β1-3-1 integrin subunit in β1-integrin-deficient GE11 cells (supplementary material Fig. S1D). Although adhesion to immobilized fibronectin was similar, cells expressing this chimera displayed strongly reduced binding of soluble fibronectin compared with cells expressing wild-type α5β1 integrin (Fig. 6A). Importantly, in addition to causing a marked inhibition of fibronectin matrix assembly, this was accompanied by a strong reduction in RhoA-GTP levels and by a random (epithelial-like) distribution of focal adhesions (Fig. 6B,C,D).
Rho-mediated contractility is required for fibronectin fibrillogenesis (Zhang et al., 1997; Zhong et al., 1998) and RhoA-GTP levels and fibronectin matrix assembly correlated for all the integrin constructs we tested. High RhoA-GTP levels were also associated with soluble fibronectin binding and fibroblast-like distribution of focal adhesions. We wondered (1) whether the high levels of RhoA-GTP were up- or downstream of soluble fibronectin binding to α5β1 integrin and the typical fibroblast-like distribution of focal adhesions and (2) whether fibronectin fibrillogenesis couples back to Rho activation in a positive feedback loop. To investigate these possibilities, binding of soluble fibronectin, fibronectin fibrillogenesis and RhoA activity were analyzed in cells expressing α5β1 under conditions where actomyosin contractility was blocked using ROCK or myosin-II inhibitors. In the presence of these inhibitors, fibronectin fibrillogenesis was strongly suppressed (ROCK) or even completely blocked (myosin-II), but binding of soluble fibronectin and RhoA-GTP levels were not affected (if anything they were slightly enhanced) (Fig. 7). These findings suggest that RhoA activity is downstream of fibronectin binding and they argue against a positive feedback loop from actomyosin contractility or fibronectin fibrillogenesis back to the regulation of Rho activity. Furthermore, the fact that the inhibitors ultimately led to disruption of focal adhesions (not shown) combined with the finding that silencing β1 in MEFs leads to a more epithelial distribution of focal adhesions (Fig. 1F) while in both cases RhoA levels remain high, argues against the possibility that the fibroblast-like cytoskeletal organization acts upstream of RhoA.
It has been reported that the transmembrane proteoglycan syndecan-4 acts in concert with integrins to mediate fibronectin matrix assembly (Chung and Erickson, 1997) and can modulate the formation of cell-matrix adhesions and the activities of Rho-GTPases, including Rac1 (Bass et al., 2007) and RhoA (Dovas et al., 2006; Saoncella et al., 1999). We investigated whether syndecan-4 played a role in the support of fibroblast-like cytoskeletal organization, Rho activity or fibronectin fibrillogenesis by α5β1 integrin. For this purpose, we silenced syndecan-4 expression in GEβ1 cells using syndecan-4 specific siRNAs. A complete knockdown of surface expression of syndecan-4 was achieved within 48 hours, whereas syndecan-4 expression was unaffected in control siRNA transfected GEβ1 cells (Fig. 8A). The formation and distribution of cell-matrix adhesions and organization of the actin cytoskeleton remained unaltered in cells without syndecan-4 (Fig. 8B). Similarly, fibronectin matrix assembly and binding of soluble fibronectin by α5β1 integrin was still intact in GEβ1 cells lacking syndecan-4 (Fig. 8C,D). Finally, α5β1-integrin-supported RhoA activation was also unaffected by syndecan-4 silencing (Fig. 8E) although for this assay, cells had to be expanded to obtain sufficient lysate resulting in incomplete syndecan-4 downregulation (not shown). Notably, a knockdown of syndecan-4 expression levels in GEβ3 cells induced a dramatic morphological change, and GEβ3 cells lacking syndecan-4 were unable to form their typical flattened circular shape but instead formed an irregular cell border containing several cytoskeletal extensions (Fig. 8F,G). These experiments indicate that syndecan-4 can act in concert with αvβ3 integrin to regulate cell-matrix adhesion distribution when α5β1 integrin is absent but syndecan-4 is not required for cytoskeletal organization, focal adhesion formation/distribution, Rho activity or fibronectin matrix assembly in the presence of α5β1 integrin.
Taken together, our data demonstrate that following the initial drop in RhoA activity during cell adhesion, the ability of α5β1 integrin to bind compact soluble fibronectin dimers drives the typical fibroblast-like distribution of focal adhesions and the accumulation of Rho activity, which, in turn, stimulates fibronectin fibrillogenesis (Fig. 9). Interactions of fibronectin with αvβ3 integrin or syndecan-4 are dispensable for all these processes.
Fibronectin fibrillogenesis requires integrin-mediated binding of soluble fibronectin dimers and depends on Rho-mediated cytoskeletal contractility to stretch integrin-bound fibronectin molecules exposing cryptic fibronectin-binding sites (Geiger et al., 2001; Mao and Schwarzbauer, 2005; Zhong et al., 1998). The α5β1 integrin mediates fibronectin matrix assembly with particular efficiency although other integrins can substitute for α5β1 integrin to some extent (Wennerberg et al., 1996; Wu et al., 1996; Yang and Hynes, 1996). Our current study indicates that α5β1 integrin not only promotes fibronectin matrix assembly, but also stimulates the contractile, fibroblast-like morphology. The ability of α5β1 integrin to efficiently bind compact soluble fibronectin dimers appears to drive the appropriate redistribution of focal adhesions to support this cell shape that is associated with increased RhoA activity, which, in turn, stimulates fibronectin fibrillogenesis. Such dynamic behavior of α5β1 integrin was previously implicated directly in fibronectin fibrillogenesis (Pankov et al., 2000). Our findings indicate that an analogous process underlies the distribution of focal adhesions leading to the typical contractile cell shape observed in fibroblasts. Integrins that cannot bind soluble fibronectin stimulate cell spreading and focal contact formation but these adhesions distribute randomly and are connected by short F-actin fibers, leading to an overall non-contractile, flat, epithelial-like cell shape. These findings point to a critical role for α5β1 integrin as an efficient mechano-transducer, which couples binding of soluble fibronectin dimers to a cytoskeletal organization that supports the assembly of a fibronectin matrix (Fig. 9).
In agreement with our findings, α5β1 integrin has recently been demonstrated to support ROCK-mediated contractility in fibroblasts (Gaggioli et al., 2007; White et al., 2007). However, others have shown that overexpression of αvβ3 integrin can stimulate RhoA activity in leukocytes (Butler et al., 2003) and CHO cells (Miao et al., 2002). Notably, these cells express endogenous β1 integrins making it difficult to compare these studies with our own. In addition, multiple different cell surface receptors can regulate the activity of Rho-GTPases and may contribute to the difference between these studies. Nevertheless, in our previous studies we were unable to observe any stimulation of RhoA activity by αvβ3 integrin in the absence of β1 integrins (Danen et al., 2002; Danen et al., 2005). Here we use Itgb3-knockout MEFs to demonstrate directly that αvβ3 integrin is dispensable for RhoA activation. Wild-type and β3-integrin-null MEFs also display the same fibroblast-like cytoskeletal organization. Moreover, a strong RNAi-mediated reduction in the expression of β1 integrins in MEFs produces a cytoskeletal organization that is very similar to that in β1-deficient cells expressing high levels of αvβ3 integrin (GEβ3). Thus, although expression of β1 integrin induces a morphological switch that resembles an `epithelial-to-mesenchymal transition' in β1-integrin-null cells (Danen, 2002), silencing β1 integrin in MEFs induces what appears like a `mesenchymal-to-epithelial transition'.
We observe a tight correlation between high RhoA-GTP levels and focal adhesion dynamics, contractile morphology, and fibronectin matrix assembly (Danen 2002; Danen, 2005) (this study). Experiments using inhibitors argue against a positive feedback loop from cytoskeletal organization to RhoA GTP loading but we do not know at present how the ability of α5β1 integrin to bind soluble fibronectin supports the activity of RhoA. Recently, the guanine nucleotide exchange factors (GEFs) Lsc and LARG were shown to link cell adhesion on fibronectin to RhoA GTP loading and focal adhesion and stress fiber formation (Dubash et al., 2007). However, the integrins tested in our study that do not bind soluble fibronectin and do not stimulate RhoA activity do in fact efficiently support the formation of focal adhesions and short stress fibers. RhoA-mediated contractility appears to be more important for the distribution of focal adhesions and orientation of stress fibers. If regulation of GEFs and GAPs (GTPase-activating proteins) is involved, our experiments using chimeric integrins indicate that obligate interactions of such proteins or their regulators with α5β1-integrin-specific residues in the cytoplasmic domains do not underlie α5β1-integrin-stimulated RhoA activation. However, it is possible that binding of soluble fibronectin to α5β1 integrin induces conformational alterations and/or clustering of the integrin that affects the localization and/or activity of such regulatory proteins.
Syndecan-4 can act in concert with integrins to regulate cytoskeletal organization during cell adhesion to fibronectin through interactions at the HepII domain in fibronectin. Using an RNAi approach we rule out the idea that crosstalk with syndecan-4 is involved in the fibroblast-like cytoskeletal organization, Rho activity and fibronectin matrix assembly that is supported by α5β1 integrin. Our findings do not seem to support the previously reported role of syndecan-4 in stimulation of RhoA-mediated processes (Saoncella et al., 1999). However, others have recently shown that during adhesion to fibronectin, syndecan-4 is required for regulation of Rac1, but not RhoA (Bass et al., 2007). This might also explain why syndecan-4 knockdown strongly affects cytoskeletal organization in GEβ3 cells in which Rac1, but not RhoA, is highly active (Danen et al., 2002).
Fibronectin serves as a ligand for numerous integrins that bind to the central cell-binding domain of fibronectin. Both α5β1 integrin and αvβ3 integrin bind to fibronectin through the RGD sequence in the fibronectin type III10 repeat, whereas only α5β1 integrin also requires an interaction with the synergy site located in the adjacent fibronectin type III9 repeat (Aota et al., 1994; Bowditch et al., 1994; Danen et al., 1995). Although α5β1 integrin and αvβ3 integrin mediate adhesion of GE11 cells to immobilized (stretched) fibronectin with similar efficiency (Danen et al., 2002), only α5β1 integrin efficiently binds compact soluble fibronectin dimers (this report). We find that this marked difference in fibronectin-binding affinity of the two integrins can be explained at least in part by the different hypervariable sequences in the ligand-binding I-like domain of the β-subunits. In agreement with Takada and colleagues, we observed that replacing this region of β1 integrin with that of β3 integrin did not affect adhesion to immobilized (stretched) fibronectin. However, we find that this swap in fact leads to a marked reduction in binding soluble fibronectin, implicating the hypervariable sequence in the regulation of fibronectin binding.
It has been demonstrated by others that integrins can be locked in low- or high-affinity states by disulfide bonds or glycan wedges in the integrin-I-like domain. However, our findings demonstrate that binding to fibronectin is an intriguingly complex process: despite the fact that αvβ3 integrin only binds to RGD in fibronectin, when it is locked in a high affinity state for RGD it fails to bind soluble and compact fibronectin dimers. This indicates that the RGD sequence in soluble fibronectin is not exposed for binding to integrins. Conformational changes upon binding of α5β1 integrin (but not αvβ3 integrin) to the synergy site in fibronectin might induce the exposure of the RGD sequence. Indeed, the tilt angle of the interdomain between fibronectin type III9 and III10 of fibronectin was shown to determine accessibility to the RGD sequence indicating that integrin binding to the synergy site may act as a modulator for RGD binding (Altroff et al., 2004).
Of the different fibronectin-binding integrins, only deletion of α5β1 integrin leads to a similar, although less severe phenotype in mice as deletion of fibronectin resulting in mesodermal and/or vascular defects causing embryonic lethality (Yang et al., 1993). The phenotype of fibronectinRGE/RGE mice is identical to that of the α5 integrin knockout (Takahashi et al., 2007) demonstrating the importance of the interaction of α5β1 integrin with the RGD motif in fibronectin. However, fibronectin matrix assembly can still occur in the absence of α5β1 integrin or the fibronectin RGD motif (Takahashi et al., 2007; Yang et al., 1993). Both in vivo and in vitro, αv integrins can compensate for the absence of α5β1 integrin or RGD, which can involve an interaction of αvβ3 integrin with fibronectin type I repeats (Takahashi et al., 2007; Yang et al., 1999; Yang and Hynes, 1996). However, differentiated α5-integrin-deficient CHO-B2 or ES cells and β1-integrin-deficient GD25 and GE11 cells poorly assemble a fibronectin matrix even in the presence of overexpressed αv integrins (Danen et al., 2002; Zhang et al., 1993) (this study). Also, the suppression of fibronectin fibrillogenesis observed in many transformed cells is often associated with loss or inactivation of α5β1 integrin function (Giancotti and Ruoslahti, 1990; Plantefaber and Hynes, 1989). Our findings suggest that even under conditions where compensatory mechanisms involving αv integrins and/or syndecans support fibronectin matrix assembly in its absence, α5β1 integrin may still be required for the typical contractile fibroblast cell shape. Such a function could explain its crucial role in mesoderm development even when fibronectin-matrices appear intact. The very high efficiency with which α5β1 integrin supports Rho-mediated contractility may also be important during processes such as angiogenesis: activated endothelial cells induce expression of α5β1 integrin and RhoA activity is required for angiogenesis to occur (Hoang et al., 2004; Kim et al., 2000).
Materials and Methods
Cell lines and plasmids
The β1-integrin-deficient GE11 cell line was described previously (Danen et al., 2002; Gimond et al., 1999). EA5 cells were derived from murine Itga5 knockout embryonic stem cells (provided by Richard Hynes, MIT, Boston, MA) were differentiated in DMEM supplemented with 10% fetal calf serum and immortalized with SV40 Large T antigen. Integrin-β3-deficient MEFs were isolated from Itgb3-knockout FVB mice (mice were provided by Richard Hynes) and immortalized with the SV40 large T antigen. All cells were cultured in DMEM supplemented with 10% fetal calf serum and antibiotics. LZRS bicistronic retroviral expression plasmids encoding human integrin β1 and integrin β3 were described before (Danen et al., 2002). cDNA encoding human α5 (provided by Erkki Ruoslahti, Cancer Research Center, The Burnham Institute, La Jolla, CA) was cloned into LZRS-neo. To generate a cDNA encoding a chimeric human α5αv integrin subunit, a fragment containing the extracellular and transmembrane domain of α5 integrin was digested from LZRS-α5 as a SwaI/HindIII fragment using the internal HindIII site immediately downstream of the transmembrane region. This was ligated to a HindIII/SnaBI cDNA fragment derived from LZRS-αv by PCR amplification of the αv integrin cytoplasmic domain in which the aggatg sequence immediately upstream of the cytoplasmic tail of αv integrin was changed to aagctt, creating a HindIII site. To generate a cDNA encoding a chimeric human β1e3t+i subunit, the Itgb1 sequence downstream of the internal SnaBI site (70 nucleotides upstream of the transmembrane region) was replaced with the corresponding sequence derived from LZRS-αv by PCR amplification in which the ccagta sequence was changed to tacgta, creating a SnaBI site. These cDNAs, as well as cDNAs encoding β3[N305T], β3[T329C;A347C] and β3[V332C;M335C] (provided by Bing-Hao Luo and Timothy A. Springer, CBR Institute for Biomedical Research, Boston, MA) and cDNA encoding β1[D130A] (provided by Yoshikazu Takada, University of California Davis Medical Center, Sacramento, CA) were recloned into LZRS-neo. The β1-3-1 expression plasmid was provided by Yoshikazu Takada. Retroviral constructs were transfected into ecotrophic packaging cells to generate virus-containing culture supernatants. β3 knockout MEFs, EA5 and GE11 cells were transfected with cDNA using effectene (Qiagen) or transduction with retroviral supernatants and positive cells were bulk sorted at least twice by FACS for the human integrin expressed.
Antibodies and other materials
Monoclonal antibodies used were anti-human α5 NKI-Sam1 (provided by Carl Figdor, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands), anti-human β1 TS/2/16, clone 18 (Transduction Laboratories), anti-human β3 C17 (provided by Ellen van der Schoot, Sanquin, Amsterdam, The Netherlands), anti-mouse β3 (clone 2C9.G2, Pharmingen), anti-paxillin (clone 349, BD Transduction Laboratories), anti-RhoA (clone 26C4, Santa Cruz), anti-Syndecan-4 (clone KY/8.2, Pharmingen), anti-vimentin (clone K36, provided by F. Ramaekers, University of Maastricht, Maastricht, The Netherlands). Texas-Red-conjugated phalloidin and Topro-3 were purchased from Molecular Probes. Texas-Red-conjugated streptavidin was purchased from Pierce Chemical Co. Human plasma fibronectin and biotinylated-fibronectin were prepared as described previously (Danen et al., 2002). GRGDSP peptide was generated at the Netherlands Cancer Institute and biotinylated using EZ-link Sulfo-NHS-Biotin (Pierce Chemical Co.) according to the manufacturer's protocol. Y27632 and blebbistatin were obtained from Calbiochem.
RhoA activity assays
Cells were plated overnight to subconfluency before lysis in Nonidet P-40 lysis buffer [0.5% Nonidet P-40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM MgCl2, 10% glycerol, supplemented with a protease inhibitor mix (Sigma-Aldrich)], and lysates were clarified by centrifugation at 20,000 g for 20 minutes at 4°C. A 1% aliquot was removed for determination of total quantities of RhoA. Clarified lysates were then incubated for 45 minutes at 4°C with a GST fusion protein of the Rho-binding domain of the Rho effector protein Rhotekin (Ren et al., 1999). Complexes were bound to glutathione-conjugated beads, and washed three times in Nonidet P-40 lysis buffer. The samples were analyzed by SDS-PAGE and western blotting.
Immunofluorescence and flow cytometry
For immunofluorescence, cells were fixed in 2% paraformaldehyde, permeabilized in 0.4% Triton X-100, blocked with 2% BSA, and incubated with anti-paxillin antibody, followed by FITC-labeled secondary antibody, phalloidin-Texas-Red and Topro-3 staining. To visualize fibronectin fibrillogenesis, cells were plated on fibronectin-coated coverslips for 4 hours and subsequently incubated for an additional 20 hours in medium containing 10% fibronectin-depleted serum supplemented with 10 μg/ml biotinylated fibronectin. Cells were fixed in 2% paraformaldehyde, blocked with 2% BSA and stained with streptavidin-Texas-Red. Subsequently, coverslips were permeabilized in 0.4% Triton X-100 and stained with Topro-3. Preparations were mounted in Mowiol 4-88 solution supplemented with DABCO (Calbiochem) and analyzed using a confocal Leica TCS-NT microscope. Images were obtained using a 40× or 63× oil objective and imported into Adobe Photoshop.
For flow cytometry of integrin expression and cell sorting, cells were trypsinized, collected in culture medium, washed with PBS, and incubated with primary antibodies in PBS containing 2% serum for 1 hour at 4°C. For flow cytometry of syndecan-4 expression, cells were harvested using enzyme-free Dissociaton buffer (Gibco), washed with 0.1% BSA/0.1% sodium azide followed by primary antibody incubation. Cells were then washed in PBS, incubated with FITC-, PE- or APC-conjugated secondary antibodies for 1 hour at 4°C, washed in PBS, and analyzed on a FACSCalibur or sorted on a FACStar plus® (Becton Dickinson).
DOC insolubility assays
Cells were labeled with biotinylated fibronectin as described above and lysed in DOC buffer [1% sodium deoxycholate (DOC), 20 mM Tris-HCl pH 8.5, 2 mM N-ethylmaleimide, 2 mM iodoacetic acid, 2 mM EDTA and 2 mM PMSF]. Lysates were passed through a 23 GA needle and DOC-insoluble material was collected by centrifugation at 20,000 g for 20 minutes at 4°C. The pellet was washed once with DOC buffer, resolved in reduced sample buffer and analyzed by SDS-PAGE and western blotting.
RGD and fibronectin binding assays
Cells were harvested, resuspended in DMEM supplemented with 0.5% BSA and 2 mM MnCl2, and incubated with 10 μM biotinylated GRGDSP-peptide or 10 μg/ml biotinylated human plasma fibronectin for 1 hour at 4°C in the absence or presence of increasing concentrations of unlabeled fibronectin. The cell pellet was washed in 0.9% NaCl and 2 mM MnCl2 and subsequently labeled with PE-conjugated streptavidin for 30 minutes at 4°C. To monitor dose-responsive fibronectin binding, cells were incubated with different concentrations of FITC-conjugated human plasma fibronectin for 1 hour at 4°C. Binding of the RGD-peptide or fibronectin was determined by flow cytometry.
Cells were plated at 40% confluency and were transfected the following day using DharmaFECT 1 reagent and a final concentration of 100 nM of integrin β1 SMARTpool siRNA (M-040783-00), Syndecan-4 ON-TARGET plus SMARTpool siRNA (L-044221-00), or siCONTROL non-targeting siRNA#2 (D-001210-02) purchased from Dharmacon. After replating, the cells were analyzed 48 hours post-transfection for integrin β1 or syndecan-4 surface expression, and used for immunofluorescence, RhoA activity assays and fibronectin binding assays.
We thank Richard Hynes for kindly providing Itgb3 knockout mice and ITGa5 knockout ES cells and Carl Figdor, Bing-Hao Luo, Frans Ramaekers, Erkki Ruoslahti, Timothy Springer, Yoshikazu Takada and Ellen van der Schoot for providing plasmids and antibodies. This work was supported by grant UL2006-3521 from the Dutch Cancer Society.
Supplementary material available online at http://jcs.biologists.org/cgi/content/full/121/15/2452/DC1
- Accepted May 16, 2008.
- © The Company of Biologists Limited 2008